Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent liver condition to date, with an estimated global prevalence of 38%.1 The progressive and inflammatory stages of ...

Advances such as triple agonists, gene editing, and microbiome therapy offer hope for metabolic diseases, but global access and early detection remain limited.

Indian pharma is hoping to cash in. Generic firms, such as Biocon, are already offering weight-loss drugs, such as cheaper ...

Conference call begins at 4:30 p.m. Eastern time todayMIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six ...

Researchers conducted the SOUL clinical trial to assess the effect of oral semaglutide on cardiovascular outcomes across different HbA1c and BMI statuses in type 2 diabetes.

Liver cancer cells thrive on fat, posing a serious risk of cancer diagnosis for millions of people living with fatty liver disease.

Wave Life Sciences Ltd. reports strong progress in RNA editing, AATD, and obesity programs with upcoming data readouts in 2025.